title: Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
abstract: FLT3 internal tandem duplication (FLT3-ITD) is usually considered as a bad marker for minimal residual disease (MRD) follow-up in acute myeloid leukemia (AML). Our objective was to evaluate the suitability of FLT3-ITD as a target for MRD detection by real-time quantitative PCR, in comparison with two other molecular MRD markers, NPM1 mutation and WT1 overexpression, in 20 adult AML patients treated in Acute Leukemia French Association (ALFA) trials. Overall, these 3 MRD markers showed comparable kinetics in 17/20 (85%) cases. Furthermore, we found that FLT3-ITD MRD levels after induction chemotherapy are predictive of complete remission duration.
authors: UR Biologie Moléculaire des leucémies et lymphomes, Faculté de Médecine de Sousse, Université de Sousse, Tunisia.
authors: Emna
authors: E
authors: Abdelhamid
authors: Claude
authors: C
authors: Preudhomme
authors: Nathalie
authors: N
authors: Helevaut
authors: Olivier
authors: O
authors: Nibourel
authors: Claude
authors: C
authors: Gardin
authors: Philippe
authors: P
authors: Rousselot
authors: Sylvie
authors: S
authors: Castaigne
authors: Bérengère
authors: B
authors: Gruson
authors: Céline
authors: C
authors: Berthon
authors: Zohra
authors: Z
authors: Soua
authors: Aline
authors: A
authors: Renneville
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D003561:Cytarabine / Q000008:administration & dosage; D005240:Feasibility Studies; D005260:Female; D020440:Gene Duplication; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D009687:Nuclear Proteins / Q000235:genetics; D000090243:Nucleophosmin; D011379:Prognosis; D060888:Real-Time Polymerase Chain Reaction; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D012680:Sensitivity and Specificity; D020080:Tandem Repeat Sequences / Q000235:genetics*; D025721:WT1 Proteins / Q000235:genetics; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: D018943:Anthracyclines; D014408:Biomarkers, Tumor; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D025721:WT1 Proteins; D003561:Cytarabine; D000090243:Nucleophosmin; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3